Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of , a preclinical candidate that acted through inhibition of the lysyl tRNA synthetase (LysRS). In this report, the full medicinal chemistry program is reviewed from the original hit through to the optimized lead. The work was guided by the first crystal structures of LysRS. The physicochemical and pharmacokinetic properties were optimized to afford compounds suitable for evaluation in mouse efficacy models of tuberculosis and with the potential for clinical development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12362622 | PMC |
| http://dx.doi.org/10.1021/acs.jmedchem.5c01331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study of independent diagnostic efficacy and co-diagnostic strategies of molecular markers for diabetic cardiomyopathy.
Front Endocrinol (Lausanne)
August 2025
Department of Endocrinology, Second Affiliated Hospital of Shandong First Medical University, Tai'an, China.
Word count of the full article: 4834Diabetic cardiomyopathy (DCM) is defined as myocardial dysfunction in diabetes mellitus (DM) patients independent of coronary artery disease (CAD) or hypertension (HTN). With high morbidity and mortality, DCM poses a significant threat to patient health. Its underlying pathogenesis remains incompletely elucidated, and the prolonged subclinical phase renders early diagnosis and precise treatment clinically challenging.
View Article and Find Full Text PDFGenetically tractable rodent models for Cryptosporidium hominis and C. parvum infections: identifying differences in infection sites between host species.
Int J Parasitol
August 2025
State Key Laboratory for Animal Disease Control and Prevention, South China Agricultural University, Guangzhou, China. Electronic address:
Cryptosporidiosis causes severe diarrhea in children and livestock. However, the absence of suitable rodent models has led to a lack of effective drugs and vaccines. In this study, genetically tractable rat and mouse models were developed for the two main causes of human cryptosporidiosis: Cryptosporidium hominis and C.
View Article and Find Full Text PDFDesign and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.
J Med Chem
August 2025
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of , a preclinical candidate that acted through inhibition of the lysyl tRNA synthetase (LysRS).
View Article and Find Full Text PDFCytokeratin-1 is essential for the detection of laminar shear stress in endothelial cells.
Anim Cells Syst (Seoul)
July 2025
Department of Biological Science & Institute of Nanosensor and Biotechnology, Dankook University, Cheonan-si, Chungnam, South Korea.
Endothelial cells regulate diverse vascular functions by perceiving and reacting to laminar shear stress. In this study, a novel shear-sensing receptor was identified through the use of a pro-inflammatory protein, lysyl-tRNA synthetase (KARS), which is known to be secreted from endothelial cells via autophagy. Binding assays demonstrated that cytokeratin-1 (CK1) interacts with KARS at the endothelial cell surface.
View Article and Find Full Text PDFAntitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas disease.
Sci Transl Med
July 2025
Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
The protozoan parasite causes Chagas disease, which is among the deadliest parasitic infections in Latin America. Current therapies are toxic and lack efficacy against the chronic stage of infection; thus, new drugs are urgently needed. Here, we describe a previously unidentified series of quinazoline compounds with potential against and the related trypanosomatid parasites and .
View Article and Find Full Text PDF